Labopharm seeking FDA dispute resolution

Labopharm says it is seeking formal FDA dispute resolution proceedings to counter an approvable letter from the agency requiring undisclosed additional work on its NDA for a once-daily formulation of the pain-reliever tramadol.

You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.